Oral vaccines
Vaxart develops tablet-based vaccines that are meant to be taken by mouth instead of by injection. Its work centers on creating vaccines for infectious diseases and testing them in studies.
Customers and revenue model
Vaxart Inc
OTC:VXRT
Vaxart Inc
OTC:VXRT
Price:
0.37
USD
-2.37%
Market Closed
Market Cap:
$89.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently viewed
Price
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Biotechnology
- Headquarters
- United States of America US
- Employees
- 110
- IPO date
- Mar 17, 1980
Vaxart is a biotechnology company that develops oral vaccines in tablet form. Instead of the usual shot, its vaccines are designed to be swallowed and to trigger an immune response through the digestive tract and mucosal surfaces. The company’s main work is research and development of vaccine candidates for infectious diseases such as respiratory and gastrointestinal viruses.
Vaxart does not sell a broad range of medicines. Its business is built around advancing vaccine programs through preclinical and clinical testing, then partnering with larger drug makers or public-health groups if a candidate looks promising. It can also receive funding tied to research contracts and development agreements, which helps support its pipeline while the products are still being tested.
What makes Vaxart different is its delivery method. Oral vaccines are easier to store, distribute, and give than many injectable vaccines, so they could fit large-scale public health use if they work well. That makes the company more of a technology developer in the vaccine supply chain than a traditional vaccine manufacturer.
